Pfizer settles with victims of Nigerian drug trial

@article{Lenzer2011PfizerSW,
  title={Pfizer settles with victims of Nigerian drug trial},
  author={J. Lenzer},
  journal={BMJ : British Medical Journal},
  year={2011},
  volume={343}
}
  • J. Lenzer
  • Published 2011
  • Medicine
  • BMJ : British Medical Journal
The drug company Pfizer has paid out $175 000 (£107 000; €120 000) to each of four families whose children died during a study of an experimental antibiotic in Kano, Nigeria. But the settlement has been strongly criticised by the families involved and by a leading ethicist in the United States, where Pfizer has its headquarters. The study was conducted during a deadly outbreak of meningitis in 1996, when some 200 children were enrolled in the study. Half were given Pfizer’s experimental… Expand
View on BMJ
ncbi.nlm.nih.gov
10 Citations
Background Citations
4

10 Citations

Citation Type

Citation Type

Ebola in west Africa.
TLDR
Concerns are raised about the importance of the work done by the numerous government and non-government organisations who have been striving since March to control the outbreak, and the Editorial highlighted antibody-based therapies such as MB003 (ZMapp), the efficacy of which substantially declined when given late in the course of experimental infection. Expand
Situating the Trovan Trial With the Use of Experimental Ebola Therapies Is Like Comparing an Apple With an Orange
  • M. Afolabi
  • Medicine
  • Journal of Bioethical Inquiry
  • 2015
TLDR
The author glaringly mixed up anthropological issues concerning the hygiene of hand-washing and safe burials in an article with a title clearly focused on ethical challenges, and failed to establish how the current Ebola epidemic ravaging some West Africa countries made these human practices ethical challenges. Expand
It is time to revise the international Good Clinical Practices guidelines: recommendations from non-commercial North–South collaborative trials
TLDR
Based on field experience in LMICs, a non-exhaustive set of recommendations for the improvement of GCP are developed, which cover 3 domains: ethical, legal and operational, and 8 specific issues: the double ethical review of ‘externally sponsored’ trials; the informed consent procedure in minors and in illiterate people; post-trial access to newly-developed products for the trial communities; the role of communities as key research actors. Expand
Quality of medicines in resource-limited settings: need for ethical guidance
TLDR
It is argued that ethically, any unjustified exceptions to medicines’ quality assurance represents a violation of the principles of beneficence and non-maleficence and an international group of experts in quality assurance/regulatory affairs and health ethicists should be set up to take up this topic and formulate a Guide to Ethical Principles of Quality Assurance of Medical Products. Expand
Benefit sharing in the revised Indian National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.
TLDR
For the revised Indian Ethical Guidelines for Biomedical and Health Research Involving Human Participants to become a positive model for other countries and ethics bodies, further elaboration of the principle and mode of implementation is needed. Expand
Seafood insecurity, bush meat consumption, and public health emergency in West Africa: Did we miss the early warning signs of an Ebola epidemic?
In this article, we frame issues around food security and the Ebola epidemic in West Africa and discuss the potential contribution of interrelated factors like seafood access, bush meat consumption,… Expand
Misconduct in Low-and Middle-Income Countries
Research misconduct is a global problem as research is a global activity. Wherever there is human activity there is misconduct. But we lack reliable data on the extent and distribution of research… Expand
Research Misconduct in Low- and Middle-Income Countries
TLDR
What is currently known about research misconduct in low- and middle-income countries is laid out, with some high profile cases summarized and suggestions on ways forward. Expand
Good Clinical Practice (GCP) and scientific misconduct
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve human subjects.
Unethical pharmaceutical manufacturer conduct worldwide and its negative impact upon pharmacy practice
  • J. Fincham
  • Medicine
  • The International journal of pharmacy practice
  • 2013